Overview

• Rubicon Research is seeking Rs 1,377.50 crore, comprising a Rs 500 crore fresh issue and a Rs 877.50 crore offer-for-sale by General Atlantic, priced at Rs 461–485 per share with subscriptions open October 9–13.
• Day-one bids covered 0.51 times the shares on offer, with investors applying for 84,62,370 shares against 1,64,55,670 available.
• The company raised about Rs 619 crore from 32 anchor investors at Rs 485 per share ahead of the launch, according to a BSE circular.
• Proceeds include roughly Rs 310 crore earmarked for debt repayment, with the balance for inorganic growth and general corporate purposes.
• Rubicon is an R&D-focused formulations player with 72 active USFDA-approved ANDA/NDA products as of June 2025 and multiple USFDA-inspected facilities in India and Canada; category reservations are 75% QIB, 15% NII and 10% retail.